vers la météo de la validation par utilisateur

Ingenuity271


precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 98 - PMID ?

In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .


Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante


Commentaires :

Analyse 0
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 1
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 2
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 3
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 4
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 5
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 6
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 7
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 8
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 9
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 10
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 11
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 12
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 13
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 14
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 15
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 16
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 17
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 18
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 19
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 20
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 21
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 22
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 23
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 24
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 25
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 26
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 27
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 28
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 29
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 30
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 31
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 32
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 33
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 34
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 35
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 36
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 37
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 38
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 39
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 40
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 41
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 42
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 43
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 44
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 45
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 46
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 47
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 48
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 49
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 50
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 51
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 52
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 53
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 54
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 55
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 56
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 57
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 58
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 59
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 60
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 61
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 62
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 63
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 64
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 65
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 66
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 67
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 68
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 69
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 70
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 71
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 72
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 73
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 74
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 75
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 76
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 77
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 78
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 79
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 80
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 81
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 82
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 83
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 84
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 85
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 86
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 87
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 88
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 89
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 90
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 91
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 92
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 93
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 94
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 95
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 96
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 97
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 98
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 99
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 100
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 101
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 102
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 103
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 104
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 105
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 106
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 107
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 108
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 109
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 110
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 111
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 112
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 113
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 114
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 115
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 116
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 117
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 118
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 119
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 120
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 121
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 122
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 123
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 124
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 125
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 126
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 127
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 128
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 129
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 130
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 131
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 132
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 133
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 134
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 135
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 136
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 137
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 138
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 139
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 140
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 141
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 142
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 143
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 144
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 145
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 146
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 147
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 148
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 149
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 150
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 151
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 152
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 153
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 154
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 155
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 156
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 157
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 158
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 159
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 160
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 161
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 162
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 163
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 164
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 165
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 166
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 167
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 168
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 169
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 170
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 171
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 172
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 173
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 174
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 175
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 176
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 177
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 178
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 179
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 180
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 181
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 182
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 183
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 184
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 185
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 186
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 187
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 188
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 189
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 190
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 191
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 192
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 193
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 194
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 195
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 196
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 197
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 198
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 199
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 200
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 201
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 202
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 203
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 204
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 205
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 206
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 207
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 208
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 209
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 210
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 211
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 212
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 213
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 214
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 215
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 216
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 217
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 218
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 219
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 220
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 221
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 222
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 223
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 224
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 225
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 226
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 227
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 228
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 229
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 230
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 231
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 232
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 233
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 234
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 235
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 236
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 237
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 238
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 239
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 240
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 241
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 242
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 243
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 244
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 245
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 246
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 247
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 248
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 249
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 250
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 251
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 252
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 253
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 254
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 255
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 256
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 257
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 258
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 259
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 260
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 261
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 262
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 263
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 264
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 265
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 266
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 267
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 268
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 269
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 270
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 271
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 272
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 273
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 274
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 275
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 276
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 277
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 278
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 279
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 280
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 281
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 282
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 283
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 284
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 285
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 286
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 287
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 288
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 289
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 290
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 291
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 292
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 293
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 294
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 295
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 296
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 297
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 298
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 299
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 300
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 301
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 302
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 303
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 304
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 305
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 306
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 307
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 308
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 309
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 310
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 311
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 312
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 313
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 314
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 315
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 316
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 317
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 318
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 319
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 320
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 321
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 322
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 323
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 324
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 325
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 326
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 327
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 328
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 329
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 330
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 331
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 332
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 333
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 334
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 335
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 336
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 337
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 338
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 339
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 340
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 341
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 342
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 343
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 344
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 345
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 346
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 347
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 348
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 349
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 350
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 351
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 352
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 353
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 354
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 355
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 356
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 357
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 358
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 359
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 360
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 361
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 362
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 363
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 364
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 365
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 366
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 367
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 368
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 369
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 370
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 371
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 372
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 373
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 374
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 375
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 376
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 377
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 378
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 379
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 380
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 381
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 382
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 383
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 384
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                            
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 385
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 386
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 387
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 388
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 389
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 390
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 391
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 392
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 393
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 394
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 395
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 396
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 397
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 398
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 399
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 400
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 401
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 402
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 403
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 404
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 405
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 406
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 407
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 408
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 409
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 410
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 411
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 412
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 413
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 414
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 415
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 416
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 417
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 418
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 419
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 420
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 421
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 422
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 423
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 424
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 425
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 426
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 427
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 428
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 429
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 430
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 431
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 432
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 433
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 434
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 435
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 436
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 437
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 438
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 439
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 440
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 441
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 442
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 443
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 444
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 445
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 446
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 447
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 448
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 449
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 450
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 451
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 452
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 453
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 454
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 455
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 456
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 457
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 458
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 459
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 460
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 461
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 462
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 463
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 464
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 465
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 466
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 467
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 468
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 469
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 470
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 471
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 472
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 473
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 474
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 475
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 476
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 477
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 478
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 479
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 480
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 481
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 482
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 483
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 484
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 485
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 486
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 487
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 488
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 489
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 490
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 491
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 492
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 493
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 494
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 495
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 496
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 497
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 498
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 499
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 500
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 501
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 502
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 503
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 504
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 505
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 506
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 507
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 508
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 509
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 510
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 511
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 512
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 513
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 514
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 515
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 516
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 517
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 518
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 519
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 520
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 521
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 522
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 523
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 524
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 525
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 526
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 527
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 528
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 529
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 530
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 531
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 532
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 533
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 534
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 535
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 536
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 537
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 538
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 539
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 540
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 541
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 542
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 543
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 544
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 545
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 546
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 547
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 548
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 549
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 550
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 551
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 552
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 553
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 554
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 555
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 556
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 557
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 558
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 559
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 560
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 561
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 562
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 563
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 564
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 565
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 566
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 567
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 568
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 569
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 570
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 571
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 572
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 573
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 574
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 575
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 576
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 577
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 578
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 579
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 580
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 581
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 582
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 583
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 584
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 585
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 586
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 587
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 588
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 589
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 590
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 591
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 592
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 593
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 594
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 595
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 596
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 597
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                            
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 598
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 599
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 600
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 601
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 602
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 603
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 604
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 605
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 606
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 607
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 608
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 609
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 610
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 611
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 612
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 613
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 614
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 615
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 616
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 617
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 618
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 619
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 620
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                            
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 621
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 622
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 623
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 624
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 625
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 626
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 627
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 628
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 629
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 630
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                            
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 631
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 632
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 633
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 634
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 635
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 636
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 637
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 638
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 639
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 640
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 641
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 642
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 643
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 644
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 645
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 646
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 647
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 648
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 649
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 650
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 651
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 652
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 653
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 654
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 655
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 656
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 657
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 658
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 659
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 660
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 661
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 662
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 663
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 664
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 665
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 666
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 667
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 668
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 669
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 670
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 671
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 672
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 673
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 674
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 675
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 676
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 677
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 678
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 679
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 680
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 681
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 682
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 683
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 684
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 685
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 686
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 687
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 688
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 689
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 690
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 691
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 692
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 693
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 694
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 695
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 696
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 697
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 698
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 699
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 700
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 701
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 702
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 703
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 704
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 705
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 706
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 707
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 708
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                            
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 709
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 710
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 711
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 712
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 713
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 714
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 715
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 716
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 717
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 718
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 719
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 720
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 721
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 722
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 723
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 724
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 725
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 726
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 727
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 728
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 729
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 730
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 731
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 732
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 733
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 734
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                            
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                     
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 735
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 736
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 737
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 738
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 739
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 740
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 741
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 742
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 743
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 744
                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                            
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                            
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +----------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                              |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                              |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+    +MOD+MOD:A+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |    |   |     |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD_ATT:N-ADJ (week,4)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)